6 results about "Cranial nerve disease" patented technology

The present invention relates to a composition for improving memory, improving cognition, preventing or treating cerebral neurological disease, comprising porcine brain enzyme hydrolysate. The composition can exhibit neuroprotective activity, brain-derived neurotrophic factor (BDNF) production activity, acetylcholinesterase inhibitory activity and reactive oxygen species (ROS) inhibitory activity.

The invention provides a TMS stimulation device which comprises a transcranial magnetic stimulation circuit and a control unit, the control unit is used for controlling the transcranial magnetic stimulation circuit to generate continuous and repeated magnetic field stimulation signals, and a small, light and high-safety household machine type can be designed to adapt to the characteristic that cranial nerve diseases need to be treated periodically and repeatedly. The action range of the stimulation probe can be effectively narrowed, a brain target stimulation area can be accurately positioned, and the problems that due to the fact that the stimulation range of the probe of an existing transcranial magnetic therapeutic instrument is too large, irrelevant brain areas except a therapeutic target area are stimulated, the therapeutic effect is not ideal, and various side effects are possibly caused are solved.

The present invention relates to a novel benfotiamine choline salt, a preparation method thereof, and a use thereof. A benfotiamine choline salt according to the present invention has excellent stability and significantly higher water solubility compared to conventional benfotiamine, thus exhibiting improved dissolution and bioavailability. In addition, a benfotiamine choline salt according to the present invention is effective to improve cognitive functions or to prevent or treat cranial nerve diseases, and thus it can be usefully applied as a pharmaceutical raw material or health functional food raw material.

We provide formulations of ion channel modulators. [Solution] The present invention partially relates to compositions or dosage forms comprising condensed heteroaryl compounds useful for preventing and / or treating diseases or conditions associated with abnormal function of voltage-gated sodium ion channels, such as abnormal delayed / persistent sodium currents. Methods for treating diseases or conditions associated with abnormal function of sodium ion channels, including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, neuromuscular disorders, trigeminal-autonomic headache (TAC), migraines, cranial nerve disorders or polycranial nerve disorders, and cortical spreading depression (CSD), are also provided herein. In another aspect, the present invention provides methods for producing ion channel modulators.

According to the AD classification prediction method and system based on the multi-mode multi-layer graph neural network model, the AD classification performance is improved by combining imaging and non-image information, and the AD classification prediction method and system have wide application potential in the field of cranial nerve diseases. According to the method, a multilayer graph neural network of a double-layer GNN architecture based on GAT and GCN is constructed based on the relationship between brain ROIs and the relationship between subjects, hierarchical training is performed on the brain ROI relationship and the subject relationship, and the performance of the model in AD classification is improved. According to the method, the Gaussian kernel function is adopted to construct the brain network between the brain ROIs as the ROI features, the process of extracting the brain region features is simplified, and the training requirement of the GNN is better met. According to the method, the multi-source non-image information matrix is constructed, the graph construction and training process of the second layer GNN is optimized, and the influence of the non-image information on the edge weight is adjusted through back propagation, so that the relationship among subjects is considered more comprehensively.

The present invention relates to a compound of formula 1 and a pharmaceutical composition containing same. This compound may be useful as: a therapeutic agent for degenerative brain diseases including dementia or cranial nerve diseases and developmental disorders caused by neural cell damage, various degenerative neural diseases, ischemic nerve diseases, or neural damage diseases; a learning ability-improving agent; and a cognitive function-improving agent. [Formula 1] in formula 1 above, B represents a part derived from retinoic acid.